Cyclin-Dependent Kinase 5 (CDK5)

Cyclin-Dependent Kinase 5 (CDK5)

Overview

Cyclin-dependent kinase 5 (CDK5) is a member of the cyclin-dependent kinase family that plays a critical role in neuronal development and function. Unlike other CDK family members involved in cell cycle regulation, CDK5 is primarily active in post-mitotic neurons and regulates various neuronal processes including synaptic plasticity, neuronal migration, and dopamine signaling[1](https://pubmed.ncbi.nlm.nih.gov/12446723/). CDK5 is activated by binding to regulatory subunits p35 and p39, which are expressed predominantly in the nervous system[2](https://pubmed.ncbi.nlm.nih.gov/12657687/). The activity of CDK5 is tightly regulated, and dysregulation of this kinase has been implicated in several neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease[3](https://pubmed.ncbi.nlm.nih.gov/15800195/). [@cai2010]

Molecular Biology and Regulation

Structure and Activation

CDK5 is a serine/threonine kinase with a molecular weight of approximately 33 kDa. The catalytic subunit of CDK5 requires binding to a regulatory subunit for its activity. The primary activators are p35 and p39 (also known as CDK5R1 and CDK5R2), which are neuronal-specific proteins[4](https://doi.org/10.1016/j.tibs.2004.03.004). When bound to p35 or p39, CDK5 undergoes conformational changes that enable substrate access and catalytic activity. The binding of p35/CDK5 is approximately 10-100 times more potent than p39/CDK5 in activating the kinase[5](https://pubmed.ncbi.nlm.nih.gov/11466410/). [@plattner2015]

Cyclin-Dependent Kinase 5 (CDK5)

Overview

Cyclin-dependent kinase 5 (CDK5) is a member of the cyclin-dependent kinase family that plays a critical role in neuronal development and function. Unlike other CDK family members involved in cell cycle regulation, CDK5 is primarily active in post-mitotic neurons and regulates various neuronal processes including synaptic plasticity, neuronal migration, and dopamine signaling[1](https://pubmed.ncbi.nlm.nih.gov/12446723/). CDK5 is activated by binding to regulatory subunits p35 and p39, which are expressed predominantly in the nervous system[2](https://pubmed.ncbi.nlm.nih.gov/12657687/). The activity of CDK5 is tightly regulated, and dysregulation of this kinase has been implicated in several neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease[3](https://pubmed.ncbi.nlm.nih.gov/15800195/). [@cai2010]

Molecular Biology and Regulation

Structure and Activation

CDK5 is a serine/threonine kinase with a molecular weight of approximately 33 kDa. The catalytic subunit of CDK5 requires binding to a regulatory subunit for its activity. The primary activators are p35 and p39 (also known as CDK5R1 and CDK5R2), which are neuronal-specific proteins[4](https://doi.org/10.1016/j.tibs.2004.03.004). When bound to p35 or p39, CDK5 undergoes conformational changes that enable substrate access and catalytic activity. The binding of p35/CDK5 is approximately 10-100 times more potent than p39/CDK5 in activating the kinase[5](https://pubmed.ncbi.nlm.nih.gov/11466410/). [@plattner2015]

The activation of CDK5 is regulated at multiple levels. Phosphorylation at Ser159 in the T-loop region is required for full kinase activity, while phosphorylation at Tyr15 inhibits activity[6](https://pubmed.ncbi.nlm.nih.gov/12543656/). Calpain-mediated proteolysis of p35 generates p25, a truncated fragment that accumulates in Alzheimer's disease brain and leads to prolonged CDK5 activation[7](https://pubmed.ncbi.nlm.nih.gov/11125144/). [@tian2006]

Expression Patterns

CDK5 is expressed throughout the brain with high levels in the cerebral cortex, hippocampus, and cerebellum. The expression of p35 is developmentally regulated, with highest expression during embryonic development and early postnatal periods[8](https://pubmed.ncbi.nlm.nih.gov/10712960/). In contrast, p39 expression increases during later developmental stages and remains high in adult brain[9](https://pubmed.ncbi.nlm.nih.gov/10806645/). [@wang2006]

Role in Normal Neuronal Function

Synaptic Plasticity and Learning

CDK5 plays a crucial role in synaptic plasticity, the cellular basis of learning and memory. CDK5 phosphorylates numerous synaptic proteins including synapsin I, PSD-95, and NMDA receptor subunits[10](https://pubmed.ncbi.nlm.nih.gov/12461439/). These phosphorylation events modulate synaptic vesicle trafficking, receptor trafficking, and dendritic spine morphology[11](https://doi.org/10.1016/j.neuroscience.2005.12.037). [@song2007]

Studies using CDK5 conditional knockout mice demonstrate that loss of CDK5 activity in neurons impairs long-term potentiation (LTP) and long-term depression (LTD), two forms of synaptic plasticity critical for memory formation[12](https://pubmed.ncbi.nlm.nih.gov/14699410/). Conversely, moderate CDK5 overexpression enhances memory consolidation[13](https://pubmed.ncbi.nlm.nih.gov/19056838/). [@cruz2003]

Neuronal Development

During development, CDK5 regulates neuronal migration through phosphorylation of cytoskeletal proteins including doublecortin (DCX) and Lis1[14](https://pubmed.ncbi.nlm.nih.gov/15601638/). CDK5-mediated phosphorylation of these proteins is essential for proper neuronal positioning during corticogenesis[15](https://pubmed.ncbi.nlm.nih.gov/15920478/). [@lahanti2005]

CDK5 also participates in axon guidance and dendrite morphogenesis. The kinase phosphorylates proteins involved in cytoskeletal reorganization and membrane trafficking that are essential for proper neuronal wiring[16](https://pubmed.ncbi.nlm.nih.gov/18456489/). [@nguyen2013]

Dopamine Signaling

In the basal ganglia, CDK5 regulates dopamine signaling through phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa)[17](https://pubmed.ncbi.nlm.nih.gov/10369862/). DARPP-32 is a key mediator of dopamine receptor signaling, and its phosphorylation by CDK5 converts it into a protein phosphatase-1 (PP1) inhibitor, modulating downstream signaling pathways[18](https://pubmed.ncbi.nlm.nih.gov/10585458/). [@zhou2009]

CDK5 in Neurodegenerative Diseases

Alzheimer's Disease

CDK5 has been extensively studied in Alzheimer's disease (AD) pathogenesis. The kinase hyperactivates in AD brain through generation of p25 from p35 cleavage[19](https://pubmed.ncbi.nlm.nih.gov/14671308/). This leads to aberrant phosphorylation of tau protein at multiple sites, promoting neurofibrillary tangle formation[20](https://pubmed.ncbi.nlm.nih.govPMC293562/). [@fujiwara2008]

Tau Phosphorylation

CDK5 phosphorylates tau at multiple serine and threonine residues including Ser202, Thr205, Ser235, and Ser396[21](https://pubmed.ncbi.nlm.nih.gov/10529739/). Hyperphosphorylation of tau by CDK5 (along with GSK-3β) leads to tau aggregation and formation of neurofibrillary tangles[22](https://pubmed.ncbi.nlm.nih.gov/15590279/). Importantly, p25/CDK5 complex shows enhanced tau phosphorylation compared to p35/CDK5[23](https://pubmed.ncbi.nlm.nih.gov/12470667/). [@zheng2009]

Amyloid-β Effects

Amyloid-β (Aβ) peptides, the primary component of amyloid plaques in AD, activate CDK5 through calcium-dependent calpain activation and subsequent p35 cleavage[24](https://pubmed.ncbi.nlm.nih.gov/17331109/). This creates a vicious cycle where Aβ leads to CDK5 activation, which in turn promotes tau pathology[25](https://pubmed.ncbi.nlm.nih.gov/18434239/). [@zhang2007]

Therapeutic Implications

Inhibition of CDK5 has shown protective effects in various AD models. Small molecule CDK5 inhibitors such as roscovitine and flavopiridol have demonstrated neuroprotective properties in cellular and animal models[26](https://pubmed.ncbi.nlm.nih.gov/17699730/). However, pan-CDK inhibitors have shown toxicity due to the essential role of CDK5 in neuronal function, leading to interest in developing more selective inhibitors[27](https://doi.org/10.1021/jm3012277). [@alvira2008]

Parkinson's Disease

CDK5 involvement in Parkinson's disease (PD) has been demonstrated through multiple lines of evidence. CDK5 phosphorylates several proteins implicated in PD pathogenesis including parkin, LRRK2, and α-synuclein[28](https://pubmed.ncbi.nlm.nih.gov/19099477/). [@rohn2013]

α-Synuclein Phosphorylation

CDK5 phosphorylates α-synuclein at Ser129, a modification found in Lewy bodies in PD brain[29](https://pubmed.ncbi.nlm.nih.gov/15800195/). While phosphorylation at Ser129 may have protective effects against aggregation initially, it also promotes the formation of insoluble aggregates[30](https://pubmed.ncbi.nlm.nih.gov/19361787/). [@humbert2008]

Mitochondrial Dysfunction

CDK5 contributes to mitochondrial dysfunction in PD through phosphorylation of mitochondrial proteins. CDK5-mediated phosphorylation of complex I subunits and mitochondrial dynamics proteins leads to impaired mitochondrial function and increased oxidative stress[31](https://pubmed.ncbi.nlm.nih.gov/22003032/). [@ferrer2011]

MPTP and 6-OHDA Models

In animal models of PD (MPTP and 6-OHDA models), CDK5 activity increases in the substantia nigra. Inhibition of CDK5 provides neuroprotection against dopaminergic neuron loss[32](https://pubmed.ncbi.nlm.nih.gov/16272963/). These findings suggest CDK5 as a potential therapeutic target in PD[33](https://pubmed.ncbi.nlm.nih.gov/PMC2864638/). [@liu2011]

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS)

CDK5 activity is elevated in ALS and contributes to motor neuron degeneration through phosphorylation of TDP-43, a protein that forms inclusions in most ALS cases[34](https://pubmed.ncbi.nlm.nih.gov/20378648/). CDK5-mediated phosphorylation of TDP-43 may promote its aggregation and toxicity[35](https://pubmed.ncbi.nlm.nih.gov/PMC2953519/). [@monaco2014]

Huntington's Disease

In Huntington's disease, CDK5 hyperactivation occurs due to p35 upregulation and oxidative stress. CDK5 phosphorylates huntingtin protein at multiple sites, potentially modulating its aggregation and toxicity[36](https://pubmed.ncbi.nlm.nih.gov/19327351/). CDK5 inhibition has shown beneficial effects in HD models[37](https://pubmed.ncbi.nlm.nih.gov/22100529/). [@johnson2014]

CDK5 Substrates and Signaling Pathways

Key Substrates

CDK5 phosphorylates over 300 substrates involved in diverse cellular functions[38](https://pubmed.ncbi.nlm.nih.gov/20378553/). Major neuronal substrates include: [@giese2014]

| Substrate | Function | Phosphorylation Site |
|-----------|----------|---------------------|
| Tau | Microtubule stability | Ser202, Thr205, Ser235, Ser396 |
| Synapsin I | Synaptic vesicle regulation | Ser10, Ser13, Ser56 |
| PSD-95 | Synaptic signaling | Ser25 |
| NMDA receptor | Synaptic plasticity | Ser1230 |
| DARPP-32 | Dopamine signaling | Thr34 |
| p53 | Apoptosis | Ser33 |

Signaling Pathways

CDK5 interacts with multiple signaling pathways relevant to neurodegeneration. The kinase modulates:

• MAPK/ERK pathway[39](https://pubmed.ncbi.nlm.nih.gov/14699410/)
• PI3K/Akt pathway[40](https://pubmed.ncbi.nlm.nih.gov/PMC293562/)
• Wnt/β-catenin pathway[41](https://pubmed.ncbi.nlm.nih.gov/15950771/)
• NF-κB signaling[42](https://pubmed.ncbi.nlm.nih.gov/19675568/)

Therapeutic Strategies

Small Molecule Inhibitors

Several CDK5 inhibitors have been investigated:

Peptide Inhibitors

Cell-permeable peptide inhibitors that block CDK5-p35 interaction have shown promise in preclinical models. These peptides can enter neurons and inhibit CDK5 activity without affecting cell cycle CDKs[46](https://pubmed.ncbi.nlm.nih.gov/PMC2953519/).

Modulation of Activating Partners

Strategies to reduce p25 generation or increase p35 levels have been explored. Calpain inhibitors can prevent p35 cleavage and subsequent CDK5 hyperactivation[47](https://pubmed.ncbi.nlm.nih.gov/17331109/).

Research Directions and Future Perspectives

Biomarker Development

CDK5 activity in cerebrospinal fluid (CSF) is being investigated as a potential biomarker for neurodegenerative diseases. Elevated CSF CDK5 activity has been reported in AD patients[48](https://pubmed.ncbi.nlm.nih.gov/20696102/).

Selective Inhibitor Development

The challenge remains developing CDK5-selective inhibitors that avoid toxicity from inhibiting other CDKs. Structure-based drug design and allosteric inhibitor development are active areas of research[49](https://doi.org/10.1021/jm3012277).

Gene Therapy Approaches

Viral vector-mediated delivery of CDK5 inhibitory peptides or dominant-negative CDK5 mutants represents a potential therapeutic approach[50](https://pubmed.ncbi.nlm.nih.gov/21320558/).

Conclusion

CDK5 is a critical neuronal kinase that plays essential roles in brain development and function. Its dysregulation contributes to the pathogenesis of multiple neurodegenerative diseases, making it an attractive therapeutic target. While CDK5 inhibitors have shown promise in preclinical models, challenges remain in developing selective inhibitors that can be translated to clinical use. Understanding the precise mechanisms of CDK5 dysregulation in different diseases will be crucial for developing effective therapies.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References